Latest Articles
Endometrial Cancer Survivors Face Harder Path to IVF Success - MedPage Today
Endometrial Cancer Survivors Face Harder Path to IVF Success MedPage Today
Published: May 30, 2026, 4:38 p.m.
'I'm fighting for time': Paramedic diagnosed with stage 4 metastatic cancer after visiting GP 21 times - portsmouth.co.uk
'I'm fighting for time': Paramedic diagnosed with stage 4 metastatic cancer after visiting GP 21 times portsmouth.co.uk
Published: May 30, 2026, 4:01 p.m.
'I'm fighting for time': Paramedic diagnosed with stage 4 metastatic cancer after visiting GP 21 times with symptoms - portsmouth.co.uk
'I'm fighting for time': Paramedic diagnosed with stage 4 metastatic cancer after visiting GP 21 times with symptoms portsmouth.co.uk
Published: May 30, 2026, 4:01 p.m.
Weight loss drugs show promise in breast cancer fight — plus more medical headlines - AOL.com
Weight loss drugs show promise in breast cancer fight — plus more medical headlines AOL.com
Published: May 30, 2026, 9:02 a.m.
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients - Cancer Therapy Advisor
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients Cancer Therapy Advisor
Published: May 30, 2026, 4 a.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical
Published: May 30, 2026, 2:16 a.m.
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC CancerNetwork
Published: May 30, 2026, 12:40 a.m.
Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer - OncLive
Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer OncLive
Published: May 30, 2026, 12:24 a.m.
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive
Published: May 29, 2026, 11:57 p.m.
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer - CancerNetwork
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer CancerNetwork
Published: May 29, 2026, 10:40 p.m.
Link copied to clipboard!